Related Experiment Video

Updated: Feb 15, 2026

Author Spotlight: Optimizing Apoplast Protein Extraction for Efficient Recovery of Recombinant Proteins from Plant Cells
05:33

Author Spotlight: Optimizing Apoplast Protein Extraction for Efficient Recovery of Recombinant Proteins from Plant Cells

Published on: July 5, 2024

2.2K

Improved cytotoxicity of novel TRAIL variants produced as recombinant fusion proteins

Malgorzata Figiel1, Piotr Bonarek1, Andrzej Górecki1

  • 1Department of Physical Biochemistry, Jagiellonian University, Gronostajowa 7, 30-387 Krakow, Poland.

Protein Engineering, Design & Selection : PEDS
|January 24, 2018
PubMed

Insights

Researchers fused Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) with the BID protein's BH3 domain to enhance its cancer-killing ability. This novel fusion protein strategy shows promise for improving TRAIL-based cancer therapies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) induces apoptosis specifically in cancer cells.
  • Cellular susceptibility to TRAIL is regulated by proteins, notably BID.
  • Enhancing TRAIL's cytotoxic potential is a key goal in cancer therapy development.

Purpose of the Study:

  • To increase the cytotoxic potential of TRAIL against cancer cells.
  • To engineer fusion proteins combining TRAIL with the BID BH3 domain.
  • To optimize buffer formulations for TRAIL fusion protein stability and activity.

Main Methods:

  • Genetic engineering to create two TRAIL-BID fusion protein variants with different linkers.
  • Analysis of protein structure and folding influenced by linker length.
  • Determination of optimal buffer conditions for TRAIL variant activity.

Main Results:

  • Fusion of TRAIL with the BID BH3 domain significantly improved TRAIL's cytotoxic activity.
  • A long linker variant, despite influencing protein structure, exhibited the highest cytotoxic effect.
  • Optimal buffer formulations were identified for the analyzed TRAIL variants.

Conclusions:

  • Fusing the BID BH3 domain to TRAIL enhances its anticancer efficacy.
  • The findings provide a basis for optimizing other TRAIL-based anticancer drugs.
  • Appropriate formulation is crucial for maintaining the native structure and efficacy of TRAIL therapeutics during storage.
Keywords:
TRAILcancer-specific cytotoxicityfusion proteinoptimal formulationprotein stability assessment

More Related Videos

Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation19:23

Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation

Published on: January 16, 2019

9.8K
Traditional Trail Making Test Modified into Brand-new Assessment Tools: Digital and Walking Trail Making Test08:07

Traditional Trail Making Test Modified into Brand-new Assessment Tools: Digital and Walking Trail Making Test

Published on: November 23, 2019

11.9K

Related Concept Videos

Nuclear Fusion02:45

Nuclear Fusion

The process of converting very light nuclei into heavier nuclei is also accompanied by the conversion of mass into large amounts of energy, a process called fusion. The principal source of energy in the sun is a net fusion reaction in which four hydrogen nuclei fuse and ultimately produce one helium nucleus and two positrons.
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
33.9K
Tagging and Fusion Proteins01:24

Tagging and Fusion Proteins

Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
8.5K
Histone Variants at the Centromere02:30

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
5.1K
Recombinant DNA01:09

Recombinant DNA

Overview
103.6K
Homologous Recombination02:31

Homologous Recombination

The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
63.7K
Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
6.9K